The study aimed to correlate the status of hepatitis C (HCV) and hepatitis B virus (HBV) co-infection in patients with human immunodeficiency virus (HIV) infection with clinical and demographic data prior to starting highly active antiretroviral therapy (HAART) and assess the impact of HCV and HBV co-infection on the natural history of HIV infection.
INTRODUCTION
The occurrence of co-infection with human immunodeficiency virus (HIV) and hepatitis B and C viral infections (HBV and HCV) is associated with their shared modes of transmission and chronic course of infection [1] [2] [3] . A number of reports indicate that the prevalence of these concurrent infections varies depending on the geographic region, ranging from 15-33% and 6-14% for HCV and HBV co-infections, respectively [4] [5] [6] [7] [8] . Interaction between these viruses may occur in the same target cells, as suggested by the presence of HBV DNA in lymphocytes, and HIV replication in the liver Kupffer' cells, and possibly in hepatocytes and stellate cells [9] . It was also shown that HIV proteins, in particular, the p24 antigen, could intensify HCV replication in vitro by increasing the expression of transforming growth factor β1 (TGFβ1) [10] [11] [12] .
Clinical studies have demonstrated that patients with HIV and HCV or HBV co-infection have lower incidence of spontaneous clearance of the hepatitis virus after acute infection, higher levels of HCV RNA in the peripheral blood, or higher degree of reactivation of HBV infection and recur-rence of markers of viral replication, including HBsAg, HBeAg and HBV DNA [13, 14] . Faster progression to liver cirrhosis and a higher prevalence of end-stage-liver-diseases (ESLD), hepatocellular carcinoma (HCC) and death were also demonstrated in HIV infected patients with HCV or/and HBV co-infection compared to patients with HCV or HBV mono-infections [13] [14] [15] [16] [17] . The influence of HCV and HBV co-infections on the natural history of concurrent HIV infection has been less well understood. Although the majority of studies show that HCV or HBV infections were not associated with more rapid progression to AIDS or death [18] [19] [20] , others have documented such association [21] [22] [23] .
In this study, we aimed to retrospectively analyze the association of HCV and HBV co-infection, with demographic, epidemiological, immunological and clinical characteristics of HIV infected patients at the point of highly active antiretroviral therapy (HAART) initiation and to evaluate their impact on the natural history of HIV infection.
PATIENTS AND METHODS
Patients who initiated HAART between January 1 st , 1998, and December 31 st 2009, at the HIV/AIDS Center of the University Hospital for Infectious and Tropical Diseases in Belgrade, were retrospectively analyzed. The only inclusion criterion was confirmed HIV infection (stages A-C according to the 1993 Centers for Disease Control case definition criteria) [24] . A total of 840 patients that fulfilled inclusion criteria were included. For each patient demographic characteristic, risk factors for HIV transmission, clinical status, CD4 cell count, HCV and HBV status, and the level of liver enzymes prior to HAART initiation were evaluated. According to the presence/absence of co-infection, all patients were stratified into four groups: 1) HIV monoinfected; 2) HIV and HCV co-infected; 3) HIV and HBV coinfected, and 4) HIV/HCV/HBV triple infected. Consent for participation was obtained from all participants, and the study was approved by the Clinical Centre of Serbia Ethics Committee.
Antibodies to HIV were determined by commercial ELISA tests, using the processor and the BEP test Enzygnost (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany). The diagnosis of HIV infection was confirmed by Western blot analysis (Bio-Rad, Marnes-la-Coquette, France). HCV infection status was determined based on the presence of anti-HCV antibodies. Determination of antibodies to HCV was performed using the commercial ELISA and Western blot assays Monolisa Anti-HCV PLUS Version 2 (Bio-Rad, Marnes La Coquette, France). HBV infection status was determined based on the presence of serological markers of HBV infection: HBsAg, anti-HBs, anti-HBcIgG, HBeAg and anti-HBe, that were also determined by the commercial enzyme immunoassay (Siemens Healthcare Diagnostics, Marburg, Germany).
The study was designed to analyze characteristics that distinguish groups of patients based on the presence of simultaneous infection of hepatitis viruses prior to study entry and before starting HAART (pretreatment characteristics). We analyzed the relationship between the indicated demographic, epidemiological, immunological and clinical characteristics of the patients before starting HAART and belonging to one of the four groups. The characteristics that contribute to group differences and determine the affiliation to one of the examined groups, we termed discriminators (predictors). By establishing discriminators for each group and identifying the differences between groups, we determined the impact of HCV and HBV co-infection on the natural course of HIV infection. Characteristics of study patients prior to starting HAART which were analyzed as potential group discriminators were: age, sex, mode of acquiring infection (man have sex with men -MSM, heterosexual, intravenous drug use -IVDU, hemophilia, blood transfusion and vertical transmission), CD4 cell count, serum level of liver enzymes (aspartate-transaminase, AST and alaninetransaminase, ALT), and the presence of clinical criteria for AIDS.
Statistics
All analyses were performed using an electronic database organized in the SPSS (version 11.5) statistical package. The association between demographic and clinical characteristics, and variables such as baseline CD4+ T cell counts, as well as other possibly related variables, was assessed using univariate and stepwise multivariate logistic regression models. Results are presented as odds ratios (OR) with 95% confidence intervals (95% CI). The level of significance (p) was 0.1 in univariate and 0.05 in stepwise multivariate logistic regression [25] .
RESULTS
Out of 840 HIV infected patients evaluated for HAART initiation, 836 were with known serologic status regarding HCV and HBV co-infections. Of these, 583/836 (69.7%) patients stratified in the first group had only HIV infection (group one). The group of HIV/HCV co-infected consisted of 201/836(24.0%) subjects (group two). The group of HIV/HBV co-infected consisted of 38/836 (4.6%) patients (group three). The triple HIV/HCV/HBV infection was recorded in 14/836 (1.7%) patients (group four). General characteristics of the studied patients are presented in Table 1 . They were mostly male (72.4%), with 62.3% younger than 40 years. AIDS was present in 55.8% of the patients prior to HAART initiation, while the remaining 44.2% were in an asymptomatic stage or had "minor" opportunistic infections. In the group of HIV mono-infected and HIV/HBV co-infected MSM were the most prevalent, while in the second and fourth group, where HCV co-infection was present, the dominant mode of transmission was via contaminated blood, primarily through intravenous drug use.
Patients with HIV mono-infection were either MSM or those who acquired HIV heterosexually and were less likely to be female, to inject drugs, to be hemophiliacs and/or blood recipients, to have AIDS as well as increased serum liver enzymes activity. According to the univariate analysis, the CD4 cell count of HIV mono-infected patients was significantly higher, compared to co-infected patients (p < 0.001) ( Table 2 ). Multivariate analysis revealed that the absence of AIDS status and transmission via blood (IVDU, hemophilia, blood transfusion) were independent predictors of HIV mono-infection ( Table 2) . Unlike HIV mono-infected, discriminators associated with HIV/HCV co-infection were found to be: female gender, IVDU, hemophilia, blood transfusion, CD4 cell count below 100 cells/µL, AIDS status, higher serum liver enzymes activity, while heterosexual mode of transmission was not associated with HIV/HCV coinfection ( Table 3) . Similar to the patients with HIV mono-infection, age and vertical mode of transmission were not statistically significant discriminators. Univariate analysis showed that, compared to the other study groups, patients with HIV/HCV co-infection were 2.5 times more likely to be women, had received blood transfusion 3.8 times more often, were hemophiliac10.0 times more frequently and were 30.3 times more likely to be IVDU. In general, most patients with hemophilia and IVDUs were also HCV co-infected. Additionally, 1.7 times more patients with HIV/HCV co-infection had severe immunodeficiency (CD4 count < 100), and had 1.6 times more frequently clinical signs of AIDS before the initiation of HAART, compared to all other investigated groups. Univariate analysis showed that HCV co-infection was linked to higher values of pretreatment serum liver enzymes and lower values of an absolute number of CD4 lymphocytes before starting HAART. Multivariate analysis showed that coinfected group HIV/HCV was predicted by female gender, hemophilia, and AIDS status before starting HAART, while heterosexual mode of transmission was a negative predictor of this group ( Table 3) .
HIV/HBV co-infection was associated with male gender, homosexual and IVDU modes of transmission, along with increased serum liver enzymes activity ( Table 4) . Important clinical and immunological parameters, such as the existence of AIDS indicative conditions before HAART, absolute number of CD4 cell count, and profound immunodeficiency (CD4 < 100) were not significantly associated to HIV/HBV co-infection compared to the other groups of patients. Multivariate analysis showed that female gender and IVDU were independent negative predictors (discriminators) of HBV coinfection ( Table 4) .
Statistically significant features that distinguish the group of patients with the triple, HIV/HCV/HBV infection compared to other tested groups of patients by univariate analysis were transmission routes: heterosexual transmission as negative and IVDU as a positive discriminator ( Table 5 ). Other demographic characteristics: age, sex, other modes of transmission (MSM, hemophilia, blood transfusion, and vertical transmission), as well as the clinical, biochemical and immunological parameters as AIDS status, absolute number of CD4 cell count, pronounced immunodeficiency (CD4 < 100) and liver enzymes activity were not discriminators for this group. Multivariate analysis revealed that IVDU was a single predictor of triple infection with statistical significance p < 0.001 (Table 5 ).
DISCUSSION
Here we present the first comprehensive study of the demographic, epidemiological, immunological and clinical features of HIV mono-infected, and HCV and/or HBV coinfected patients in Serbia. Based on the differences in these characteristics among the examined groups, we evaluated the impact of HCV and HBV co-infection on the natural history of HIV infection among patients followed within the Serbian patient cohort. The first AIDS cases in Serbia were registered in 1985 [26] . According to the latest data released by the Institute for Public Health (IPH) of Serbia "Dr Milan Jovanović Batut", the national institution that has the mandate for surveillance, monitoring and evaluation of the national response to HIV/AIDS, the cumulative number of HIV-infected people reported till 31 st December 2015 was 3312, of whom 1788 developed AIDS while 1192 died [26] . In 2015, 178 newly diagnosed HIV cases, 45 AIDS cases and 15 AIDS-related deaths were reported to IPH of Serbia. The decreasing trend of AIDS cases and AIDS-related deaths is observed in the last decade, as the result of the introduction of HAART [26] . Treatment of people living with HIV (PLHIV) in Serbia is in general based on the latest recommendations given by European AIDS Clinical Society [27, 28] . About 1500 PLHIV are currently being treated in Serbia [26] , and nearly 60 % of them were participants of our study.
The prevalence of concurrent HIV and HCV and/or HBV infection in the world varies depending on the region and the overall prevalence in the general population [29, 30] . Rosenthal and colleagues reported that in Western Europe, the prevalence of HIV/HCV co-infection is 15 -30% [31] . A similar frequency of these co-infections was also published for the United States [32, 33] . According to the results of many studies, the prevalence of HIV/HBV co-infection in Europe and the USA amounted up to 4 -14% [5, 34, 35] . Consistent with these data, the prevalence of simultaneous hepatitis viral infections in patients with HIV infection in our study was 25.7% HIV/HCV, 6.3% HIV/HBV, and 1.7% HIV/HCV/HBV.
Patients with concurrent hepatitis C and B viral coinfections significantly differed regarding the modes of HIV transmission in our study. Specifically, the sexual mode of HIV transmission was dominant in the group with HIV mono-infection, and in those with HBV co-infection, while in patients with HCV co-infection the IVDU was the most prevalent one. These data confirm that HBV co-infection is more frequent in the population of MSM [36, 37] , and HCV in the population of IVDU [32, 38] , which might change the epidemiological situation in Serbia in the future. Unlike the beginning of the AIDS epidemic in Serbia, when the prevailing transmission of infection was through blood, especially IVDU [26] , at the present time the prevailing mode of transmission is through sexual contacts, primarily homosexual [26] . This could reduce the prevalence of HCV co-infection and increase the prevalence of HBV co-infection in patients with HIV infection in Serbia.
The findings of our study indicate a significant influence of concurrent HCV infection on the natural history of HIV infection, as patients with HCV co-infection had a higher risk of progression to profound immunodeficiency and AIDS over time, compared with patients with HIV mono-infection. These features might be linked to the fact that majority of coinfected patients were intravenous drug users (IVDUs). Intravenous drug use per se causes many health problems and therefore might accelerate the progression of immunodeficiency [39, 40] . Furthermore, IVDUs have repeatedly been associated with low level of responsibility towards their health, and hesitation to seek for medical help, what puts them at high risk for disease progression [41] [42] [43] . However, considering that majority of IVDUs in our study were undergoing treatment for addiction, which improves their awareness and responsibility towards health and socialization, other causes for rapid progression to AIDS in HIV/HCV coinfected patients should also be considered. One of those might be direct impact of HCV infection on the natural course of HIV infection. Previous studies in this area, carried out in the mid-nineties, showed that patients with concurrent HIV/HCV infection progressed to AIDS more quickly and had shorter survival time than patients who only had HIV infection [44, 45] . Greub et al. had similar results in their study of a Swiss HIV cohort [22] . In contrast, in a prospective study of 1995 patients with HIV infection in the United States, Sulkovski et al. found no difference in the appearance of AIDS defining conditions, in the reduction of the number of CD4 lymphocytes below 200 cells/μL, or in survival time of patients with HIV/HCV co-infection as compared to patients with HIV mono-infection [46] . Other studies in Europe and USA also showed that there was no difference in the rate of progression to AIDS and in survival between patients with HIV/HCV co-infection and patients with HIV infection who had no concomitant infection with this hepatitis virus [47] [48] [49] . The study of Zhang et al. even suggested that HCV infection was associated with slower progression of the natural course of HIV infections, as they found that patients with HIV mono-infection at baseline had a significantly lower CD4 and more HIV RNA copies compared to patients with HIV/HCV co-infection [50] . Moreover, after 33 months of follow-up, significantly fewer patients in the HIV/HCV infection have progressed to AIDS, defined by a reduction in the number of CD4 values of less than 200 cells/μL [50] . The results of our study are in line with those that indicate the adverse impact of HCV on the natural course of HIV infection in patients with HIV/HCV co-infection. The negative impact of HCV infection could be explained by constant immune activation caused by chronic HCV infection, causing transcription of HIV in infected activated CD4 lymphocytes which accelerates their destruction, thus deepening immunodeficiency and contributing to progression to AIDS [51] . In addition, some authors have demonstrated active HCV replication in lymphoid tissue, CD4 lymphocytes of peripheral blood, CD34 progenitor cells, and lymphoblastoid cells [52] [53] [54] . The correlation that exists between HCV infection in peripheral blood mononuclear cells and their apoptosis could explain the more pronounced immunodeficiency in the natural course of HIV/HCV co-infection compared to the natural history of HIV mono-infection [54] [55] [56] .
In the last 20 years numerous studies on the impact of HBV co-infection in the natural course of HIV infection have been carried out [57] [58] [59] . The finding that HBV although primarily hepatotropic also displays tropism for lymphoid cells, increased the likelihood of interaction of HIV and HBV at the cellular level, in patients with HIV/HBV coinfection [60, 61] . In addition to the CD4+ T cell subpopulation, HBV also replicates in PBMC subsets of HBV/HIV-1 patients [62, 63] . Some studies have shown that the HBV-X protein (HBX) accelerates existing HIV replication, inducing transcription of the HIV LTR sequences [64] . Chun et al. and Tsai et al. showed the influence of HBV infection to faster progression of the natural course of HIV infection [65, 66] . Also, in the study of Ockenga et al. the adverse impact of HBV co-infection on survival of patients with AIDS, was reported [67] . On the other hand, three longitudinal studies haven't shown the impact of HBV co-infection on CD4 depletion on progression to AIDS, or on mortality in patients with HIV/HBV co-infection [57, 68, 69] . EuroSIDA cohort study that examined 9802 patients in 72 centers showed that HBsAg-positive patients with HIV infection have a significantly lower number of CD4 lymphocytes and higher levels of HIV RNA copies before HAART, compared to HBsAgnegative patients, however, the authors of that study did not attribute the adverse influence of the HBV co-infection to changes of the natural course of HIV infection but instead to a longer duration of HIV infection in HBsAg positive patients [68] . The results of our study showed no effect on HBV co-infection depletion of CD4 lymphocytes and progression of HIV infection, as CD4 cell count before HAART, severe immunodeficiency (CD4 < 100), and AIDS status were not identified as significant independent discriminators for the group of patients with HIV/HBV coinfection.
Contrary to some previous studies [70, 71] in our cohort HCV/HBV co-infection did not have a significant influence on the natural history of HIV infection. Our findings are in accordance with the study of Kallas E. et al. who also showed that HBV/HCV co-infection does not significantly affect the number of CD4 lymphocytes in patients with HIV/HBV/HCV triple infection [72] . However, it may also be speculated that a small total number of patients in this group could have influenced our results. It has been shown that HCV/HBV co-infection is characterized by mutual inhibition of viral replication, and consequently slower progression of chronic hepatitis caused by these viruses [73, 74] . Some data indicate that chronic HCV/HBV co-infection in patients with HIV infection is also characterized by reciprocal inhibition of the viral genome and that these two hepatitis viral infections do not cause more rapid progression of HIV infection to AIDS [75] .
The duration of the recorded HIV epidemic in Serbia is similar to the one in Western European countries, with changing dynamics in respect to the most prevalent mode of transmission -from initially recognized and prevailing among IVDUs in the mid-eighties to the lately mostly spreading in the MSM population [76] . Although considered as low prevalence country, the number of new cases is constantly growing and the epidemic in Serbia is among the most abundant in the region [77] . Clinical features and outcome of HIV infection in Serbia have been reported [78, 79] , however, very few studies have addressed different aspects of co-infection with hepatitis viruses [80, 81] .
Our study was based on serological confirmation of patients HBV and HCV infection status, which can be considered as a significant limitation. However, being a retrospective study and in view of the very difficult socioeconomic situation throughout the studied period, it reflects the clinical reality when there had been no access to nucleic acid-based tests in virological diagnosis. Nevertheless, in this perspective, even if the presented findings might not be seen as based on confirmed co-infection status, they do reflect the effect of previous contact with HBV and/or HCV infection, which we still find to be very clinically relevant.
CONCLUSION
The results of our study clearly show that concomitant HCV infection deepens immunodeficiency and is associated with increased frequency of clinical signs of AIDS in HIV patients who are not receiving HAART. On the other hand, simultaneous HBV and HCV/HBV infection have no impact on the natural course of HIV infection. Having in mind the unfavorable influence of HCV on the natural history of HIV infection, it is important to analyze the influence of HCV on the immune reconstitution after initiation of HAART among patients with HIV/HCV co-infection, which is the subject of our ongoing research. In order to prevent its unfavorable influence on the progression of HIV infection, it is necessary to improve the treatment of HCV infection in patients with HIV/HCV co-infection in Serbia, particularly because interferon-free regimens are not available, whereas access to peginterferon and ribavirin is limited.
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